Avanir Pharmaceuticals (NASDAQ: AVNR) is dedicated to acquiring, developing, and commercializing innovative therapeutic products designed to treat chronic diseases. Zenvia™, the company’s lead product candidate, is currently being developed to treat pseudobulbar affect (PBA). GlaxoSmithKline Consumer Healthcare currently markets Avanir’s first commercialized product, Abreva®, in North America. Abreva is the leading over-the-counter product for the treatment of cold sores. For further information, visit the Company’s web site at www.avanir.com.
- 17 years ago
QualityStocks
Avanir Pharmaceuticals (NASDAQ: AVNR)
Tags Rodman & Renshaw
Related Post
-
QualityStocksNewsBreaks – Izotropic Corporation (CSE: IZO) (OTCQB: IZOZF) (FSE: 1R3) Featured in NetworkNewsWire Editorial on AI-Driven Breast Cancer Imaging
Izotropic (CSE: IZO) (OTCQB: IZOZF) (FSE: 1R3) announced its inclusion in a NetworkNewsWire (“NNW”) editorial titled…
-
QualityStocksNewsBreaks – Forward Industries, Inc. (NASDAQ: FORD) Featured in Oak Ridge Financial Research Report Highlighting Transition to Solana Digital Asset Treasury Model
Forward Industries (NASDAQ: FORD) has been featured in a new research report by Oak Ridge…
-
QualityStocksNewsBreaks – Soligenix Inc. (NASDAQ: SNGX) Advances HyBryte(TM) as Potential First-Line CTCL Treatment with Promising FLASH Results
Soligenix (NASDAQ: SNGX) is continuing to build momentum in the treatment of early-stage cutaneous T-cell…